Previous 10 | Next 10 |
In a statement , FDA Commissioner Scott Gottlieb, M.D. says the agency has submitted its request for $6.1B in funding for fiscal 2020, an increase of $643M from this fiscal year. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla ...
Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, ...
The broad market's down day notwithstanding, opioid drugmakers are under modest pressure in apparent response to a report that privately held Purdue Pharma is mulling a Chapter 11 bankruptcy filing to protect itself from the ~2,000 lawsuits against it related to its marketing practices for...
Dr. Reddy’s Laboratories Ltd. ((BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today the re-launch of its Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg...
The U.S. Supreme Court has rejected the state of Maryland's appeal of an appeals court ruling that struck down its anti-price gouging law citing the illegality of state-level regulation of interstate commerce. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology E...
In a statement , FDA commissioner Scott Gottlieb, M.D. announces a new pathway for accelerated view of marketing applications from generic drugmakers for off-patent branded medicines facing no generic competition, a situation characterizing "hundreds" of such drugs that serve small patient ...
Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Adcirca (tadalafil) Tablets i...
The U.S. Court of Appeals for the Federal Circuit has denied a motion from Indivior ( OTCPK:INVVY -5.2% ) for a rehearing to reinstate the preliminary injunction against Dr. Reddy's Laboratories ( RDY +0.7% ) stopping it from marketing a generic version of opioid dependence treatm...
Dr. Reddy’s Laboratories (NYSE: RDY ) is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetam in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags to the hospital level in U.S. More news on: Dr. Reddy's Laboratories Limited,...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that its wholly owned subsidiary, Dr Reddy’s Laboratories, Inc, is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetam in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL (15 mg...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2024. The information mentioned in this release is based on consolidated financial statements under International Fina...
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...